InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Martin Samuel Bates, Chief Financial Officer. Officer active across 1 companies, notably Celldex Therapeutics, Inc.. Aggregated, 6 filings have been logged. The latest transaction was filed on 23 December 2021 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations6 total
€25,8663,250 shares@ €7.95890.0011% mcap19.8% of flow
Common Stock
SEC:0001179110-21-011251·
€25,8663,250 shares@ €7.95890.0011% mcap9.9% of flow
Common Stock
SEC:0001179110-21-011251:0·
€25,6113,250 shares@ €7.88040.0010% mcap19.6% of flow
Common Stock
SEC:0001179110-21-010208·
€25,6113,250 shares@ €7.88040.0010% mcap9.8% of flow
Common Stock
SEC:0001179110-21-010208:0·
€79,23310,302 shares@ €7.69110.0032% mcap60.6% of flow
Common Stock
SEC:0001179110-21-008140·
€79,23310,302 shares@ €7.69110.0032% mcap30.3% of flow
Common Stock
SEC:0001179110-21-008140:0·
6 of 6 declarations
About Martin Samuel Bates
Samuel Bates Martin is the Chief Financial Officer and Senior Vice President of Celldex Therapeutics, Inc. He is responsible for the financial management of the company, overseeing accounting operations and financial reporting. Samuel Bates Martin plays a key role in developing financial strategies to support the growth of Celldex.
